Soru

Zorluk: KolayGeneral Internal Medicine

Match each patient's clinical presentation with the most appropriate initial pharmacological intervention.

  • A 45-year-old man with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 22% and an LDL cholesterol of 145 mg/dLInitiate a high-intensity HMG-CoA reductase inhibitor
  • A 50-year-old woman with newly diagnosed type 2 diabetes mellitus, a hemoglobin A1c of 7.8%, and normal renal functionInitiate a biguanide
  • A 60-year-old man with newly diagnosed primary hypertension and osteoporosis, with no history of diabetes or heart failureInitiate a thiazide diuretic
  • A 55-year-old woman with chronic kidney disease, severe albuminuria, and newly diagnosed primary hypertensionInitiate an angiotensin-converting enzyme inhibitor

Cevap

The correct matches pair each specific clinical presentation with its guideline-directed first-line pharmacological therapy.
Each correct pairing reflects the standard of care for initial pharmacological management in primary care: statins for high ASCVD risk, biguanides for uncomplicated type 2 diabetes, thiazides for hypertension with osteoporosis, and ACE inhibitors for hypertension with proteinuric CKD.

Adım Adım Çözüm

1
Analyze the lipid profile and ASCVD risk.
Identify the indication for a high-intensity statin.
Current guidelines recommend high-intensity statin therapy for primary prevention in patients with a 10-year ASCVD risk of 20% or higher.
2
Analyze the new diabetes diagnosis.
Identify the indication for metformin.
A biguanide is the established first-line agent for newly diagnosed type 2 diabetes mellitus.
3
Analyze the hypertension case with comorbid osteoporosis.
Identify the indication for a thiazide diuretic.
Thiazides promote renal calcium reabsorption, improving bone mineral density while effectively lowering blood pressure.
4
Analyze the hypertension case with comorbid CKD and albuminuria.
Identify the indication for an ACE inhibitor.
ACE inhibitors reduce intraglomerular pressure, specifically slowing the progression of proteinuric kidney disease.

Anahtar Kavram

First-line pharmacological management of common outpatient chronic diseases
Bu soruyu puanla